Psychiatric Digital Biomarkers Market Size Worth USD 5,464.37 Million by 2034 | CAGR: 24.1%

The global psychiatric digital biomarkers market size is expected to reach USD 5,464.37 million by 2034, according to a new study by Polaris Market Research. The report “Psychiatric Digital Biomarkers Market Size, Share, Trends, Industry Analysis Report: By Type (Wearable, Mobile-Based Applications, Sensors, and Others), Clinical Practice, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

What Is the Psychiatric Digital Biomarkers Market?

Psychiatric digital biomarkers are measurable behavioral, cognitive, and physiological signals collected through digital technologies to understand mental health conditions. These signals can be captured using wearable devices, smartphone applications, biosensors, and digital monitoring platforms. They include sleep patterns, physical activity, heart rate variability, speech, and changes in daily routines.

These tools enable researchers and healthcare professionals to track symptoms, investigate responses to treatment, and find patterns related to conditions like depression, anxiety, bipolar disorder and schizophrenia. They also assist pharmaceutical research by providing additional data for clinical trials. Digital biomarkers are complementary to, but do not substitute, professional assessments and clinical diagnosis.

Growing Demand for Continuous Mental Health Monitoring Supports Market Growth

Traditional mental health assessments often take place during scheduled appointments, making it difficult to understand changes in symptoms between visits. Digital biomarkers can provide ongoing information about patients' daily activities, sleep, and physiological responses. This can help healthcare professionals and researchers develop a clearer picture of symptom patterns and treatment outcomes.

In June 2026, the Digital Medicine Society (DiMe) released its Digital Measures Set for Common Mental Health Disorders. Developed with more than 20 industry, advocacy, and research partners, the resource includes measures related to sleep, physical activity, cognitive function, speech, autonomic function, and facial and gaze features. The initiative supports more consistent measurement of mental health outcomes in clinical research and care.

Advances in AI and Multimodal Analysis Create New Opportunities

To analyze large volumes of behavioral and physiological data AI and machine learning are expanding the ability. By examining different signals together, these technologies can help researchers identify patterns that may be difficult to detect through individual measurements. For remote assessment and personalized mental healthcare smartphone-based monitoring, voice analysis, and wearable sensors are also creating opportunities.

The Annual Meeting of the American Society of Clinical Psychopharmacology hosted the announcement of clinical validation results for Emobot Health's EMOCARE smartphone-based depression monitoring tool in May 2026. It monitors depressive symptoms by analyzing signals such as voice, facial expression, movement and screen behavior. The results show an increasing interest in passive, multimodal monitoring for psychiatric research and treatment follow up.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: Psychiatric Digital Biomarkers Market Report

Psychiatric Digital Biomarkers Market Report Highlights

• North America accounted for 58.2% of the psychiatric digital biomarkers market revenue in 2025, maintaining its leading position. Advanced healthcare infrastructure, investments in digital health technologies, and growing adoption of AI based mental health tools support regional demand.
• During 2026–2034 Europe is projected to register the highest CAGR of 25.6%. Government initiatives, digital health transformation, and growing research into mental health monitoring are supporting regional growth.
• In 2025 the wearable segment accounted for 39.4% of market revenue. Increasing use of smartwatches, fitness trackers, and wearable EEG devices supports demand for continuous monitoring.
• The mobile-based applications segment is projected to register a CAGR of 26.3% during 2026–2034. Growing smartphone use, passive data collection, and AI-based behavioral analysis are supporting segment growth.
• In 2025 the healthcare companies segment accounted for 50.3% of market revenue. Increasing use of digital biomarkers in pharmaceutical research, clinical trials, and treatment response assessment supports its position.

Where Is the Psychiatric Digital Biomarkers Market Headed?

The market is moving toward continuous monitoring, multimodal data analysis, and more personalized approaches to mental healthcare. Wearable devices and mobile applications can collect information outside clinical settings, while AI-powered platforms can help organize and interpret these data for research and clinical review.

Collaboration among healthcare companies, technology developers, and research institutions is also supporting innovation. However, data privacy, clinical validation, and the need for reliable measurement standards remain important considerations for wider adoption.

What Does the Psychiatric Digital Biomarkers Market Report Reveal?

• What is the global psychiatric digital biomarkers market size, and what CAGR is projected during 2026–2034?

• Who are the key industry players, and what is their relative position in the competitive landscape?

• What are the major factors contributing to the expansion of the psychiatric digital biomarkers market?

• How do different end-use segments, including healthcare companies, healthcare providers, and payers, influence the market landscape?

• How does the market differ by type, clinical practice, end use, and geography? Which segment holds the leading market share?

• What opportunities exist across regional markets, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?

• What emerging technologies and innovations are shaping the psychiatric digital biomarkers market?

Psychiatric Digital Biomarkers Market report on the basis of type, clinical practice, end use, and region:

By Type Outlook (Revenue – USD Million, 2021–2034)

• Wearable
• Mobile-Based Applications
• Sensors
• Others

By Clinical Practice Outlook (Revenue – USD Million, 2021–2034)

• Diagnostic Psychiatric Digital Biomarkers
• Monitoring Psychiatric Digital Biomarkers
• Predictive and Prognostic Psychiatric Digital Biomarkers
• Others

By End Use Outlook (Revenue – USD Million, 2021–2034)

• Healthcare Companies
• Healthcare Providers
• Payers
• Others

By Regional Outlook (Revenue – USD Million, 2021–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America